Blockade of growth hormone receptor signaling by using pegvisomant: A functional therapeutic strategy in hepatocellular carcinoma is a research paper published in Frontiers in Oncology (2022). On theSindex it has a DataRank of 0.489. It has been cited 25 times.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.489
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →National Institutes of Health
Grant: 5R21CA170035-02
Integrating plasma IGF-1 into novel classification of hepatocellular carcinoma
National Institutes of Health
Grant: 1R01CA151533-01A1
Role of IGF-IR tyrosine kinase in NPM-ALK-expressing T-cell lymphoma
National Institutes of Health
Grant: 5R01CA260872-03
A Phase II and Biomarker Study of Dual VEGF/PD-L1 Blockade in Neoadjuvant Setting in Resectable HCC Patients
National Institutes of Health
Grant: 5R21CA190945-02
Novel Point-of-Care Tool to Predict Response to Sorafenib in Hepatocellular Carcinoma
Fields of Study
Keywords
Sustainable Development Goals